Brokers Offer Predictions for Ekso Bionics Holdings, Inc.’s FY2016 Earnings (EKSO)
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Stock analysts at B. Riley cut their FY2016 earnings estimates for shares of Ekso Bionics Holdings in a research note issued to investors on Thursday. B. Riley analyst G. Chodaczek now anticipates that the brokerage will post earnings of ($2.06) per share for the year, down from their previous estimate of ($1.87). B. Riley has a “Buy” rating and a $8.00 price objective on the stock. B. Riley also issued estimates for Ekso Bionics Holdings’ Q1 2017 earnings at ($0.37) EPS, Q4 2017 earnings at ($0.40) EPS and FY2017 earnings at ($1.52) EPS.
EKSO has been the subject of several other reports. SunTrust Banks Inc. initiated coverage on Ekso Bionics Holdings in a report on Thursday, October 13th. They set a “buy” rating and a $8.00 price target for the company. Zacks Investment Research upgraded Ekso Bionics Holdings from a “sell” rating to a “hold” rating in a report on Thursday, August 11th. Finally, Rodman & Renshaw restated a “buy” rating on shares of Ekso Bionics Holdings in a report on Sunday, July 31st.
Ekso Bionics Holdings (NASDAQ:EKSO) opened at 4.04 on Monday. The stock’s 50 day moving average is $4.93 and its 200-day moving average is $5.12. Ekso Bionics Holdings has a 1-year low of $3.45 and a 1-year high of $10.08. The firm’s market capitalization is $66.39 million.
Large investors have recently bought and sold shares of the company. Northern Trust Corp bought a new stake in Ekso Bionics Holdings during the third quarter valued at $130,000. Spark Investment Management LLC bought a new stake in Ekso Bionics Holdings during the third quarter valued at $185,000. Finally, KCG Holdings Inc. bought a new stake in Ekso Bionics Holdings during the third quarter valued at $186,000.
Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.